Myasthenia Gravis Trial, Recruiting NCT05564936 Sponsor: Ad scientiam Condition: Myasthenia Gravis
Back to Myasthenia Gravis

Myasthenia Gravis Trial, Recruiting

NCT05564936
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with generalized Myasthenia Gravis (gMG) with widespread muscle weakness of a certain level of severity, and you are not expected to need a breathing machine during the study
  • You have had a blood test that came back positive for a specific antibody linked to MG (called anti-AChR)
  • You have read and signed the consent form agreeing to take part
  • You own a personal smartphone running iOS version 13 or higher, or Android version 8 or higher
  • You are able to use a smartphone comfortably
  • You are able to read French, English, or Spanish, and can understand simple picture-based instructions

Who may not be able to join:

  • You have had a thymus gland removal, plasma exchange therapy, or intravenous immunoglobulin treatment within the last four weeks before the study check-in
  • You have started a specific type of treatment called an FcRn inhibitor within the four weeks before the study check-in
  • You have a medical or psychological condition that, in the doctor's opinion, could affect your ability to participate fully or safely
  • You are currently pregnant or breastfeeding
  • You are under a legal guardianship or curatorship arrangement
  • You currently have issues with drug or alcohol use that could affect your performance in the study, as judged by the doctor
  • You are already taking part in another MG-related clinical study called ME&MG
  • You have taken part in another clinical trial within the last 30 days, or are currently in another trial that could interfere with this one

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33147107752

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ad scientiam
Registry
ClinicalTrials.gov
Start date
24 January 2024
Est. completion
24 September 2025

Where this trial is recruiting

🇫🇷 France 🇺🇸 United States

Primary endpoints

To demonstrate that ME&MG tests results performed at-home, under unsupervised condition, are correlated to standard tests results performed in-clinic, under supervised conditions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov